Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 19c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $112.21 million versus the consensus estimate of $110.29 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Jack in the Box completes $500M securitized debt refinancing
• Wealthfront launches custodial account with tax-gain harvesting